TP53

ASCO 2019 | Activity of venetoclax-based therapy in TP53-mutated AML

L:

Guillermo Garcia-Manero, MD Anderson Cancer Center, talks to the AML Global Portal (AGP) at ASCO 2019, Chicago, US, about the use of venetoclax in combination with hypomethylating agents; FLAG-Ida, low dose Ara-C or CPX-351 for TP53-mutated acute myeloid leukemia (AML).